For licensed healthcare professionals. The protocol figures below are drawn from published labeling and peer-reviewed literature for educational reference. They are not a prescription, not a recommendation, and not a substitute for the dispensing pharmacy's labeling or your own clinical judgment.

GLP-1 / Incretin

CagriSema

aka Cagrilintide + Semaglutide

Not WADA-listed

Fixed-dose combination of amylin analog cagrilintide with semaglutide. Phase III REDEFINE program.

At a glance

Common vial size: 5 mg
Reference dose: 2.4 mg
Frequency: Once weekly

Reference titration protocol

Combined cagrilintide + semaglutide; 0.25 → 2.4 mg ladder, weekly.

Reference titration ladder for CagriSema
Step	Dose	Duration	Administrations / week
1	250 mcg	4 weeks	1×
2	550 mcg	4 weeks	1×
3	850 mcg	4 weeks	1×
4	1.15 mg	4 weeks	1×
5	1.45 mg	4 weeks	1×
6	1.75 mg	4 weeks	1×
7	2.05 mg	4 weeks	1×
8	2.35 mg	4 weeks	1×

Reconstitution example

A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL. Confirm the diluent and volume against the labeling that ships with the vial.

Open this configuration in the calculator

References

REDEFINE-1 readout (Novo Nordisk)

Often used with

Compounds commonly discussed alongside CagriSema in published protocols and prescriber requests. Listed for reference only — not a clinical recommendation, and not a suggestion to co-administer.

Pricing and ordering are for verified accounts

VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.

Also in GLP-1 / Incretin

Semaglutide

GLP-1 receptor agonist for type 2 diabetes and chronic weight management. Standard 16-week titration to target dose.

Tirzepatide

Dual GIP/GLP-1 receptor agonist. 5-dose escalation (2.5 → 15 mg) over 20+ weeks. Up to ~22% weight loss in SURMOUNT-1.

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist. Phase III; ~24% weight loss reported in Phase II at 48 weeks.

Survodutide

Dual GLP-1/glucagon agonist. Phase III for obesity and MASH. ~52% liver-fat reduction reported in Phase II.

Educational information for licensed healthcare professionals

The material on this page is general educational information intended for licensed healthcare professionals and their clinical staff. It is not medical advice, is not a substitute for professional judgment, and does not establish a provider-patient relationship. Nothing here should be read as a recommendation for, or endorsement of, any specific therapy, product, or course of treatment. Compounded preparations must be handled in accordance with applicable federal and state law, the dispensing pharmacy's labeling, and your own institutional policies. All clinical decisions — including product selection, preparation, dosing, and administration — remain the sole responsibility of the treating licensed practitioner.

VitaRelay is a technology and logistics network. We are not a pharmacy, prescriber, or distributor. See our Terms of Service and service availability for details.